Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 - LBA: immunogenicity, biomarkers and PK assays).

Gupta S, Richards S, Amaravadi L, Piccoli S, Desilva B, Pillutla R, Stevenson L, Mehta D, Carrasco-Triguero M, Neely R, Partridge M, Staack RF, Zhao X, Gorovits B, Kolaitis G, Sumner G, Stubenrauch KG, Zou L, Amur S, Beaver C, Berger I, Berisha F, Birnboeck H, Bower J, Cho SJ, Cludts I, Cocea L, Donato LD, Fischer S, Fraser S, Garofolo F, Haidar S, Haulenbeek J, Hottenstein C, Hu J, Ishii-Watabe A, Islam R, Jani D, Kadavil J, Kamerud J, Kramer D, Kurki P, MacMannis S, McNally J, Mullan A, Papadimitriou A, Pedras-Vasconcelos J, Ray S, Safavi A, Saito Y, Savoie N, Fjording MS, Scheibner K, Smeraglia J, Song A, Stouffer B, Tampal N, der Strate BV, Verch T, Welink J, Xu Y, Yang TY, Yengi L, Zeng J, Zhang Y, Zhang Y, Zoog S.

Bioanalysis. 2017 Dec;9(24):1967-1996. doi: 10.4155/bio-2017-4974. Epub 2017 Dec 5.

2.

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.

Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Gemmy Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G.

EMBO Mol Med. 2017 Jul;9(7):985. doi: 10.15252/emmm.201707895. No abstract available.

3.

3-(4-Hydroxyphenyl)propionic acid: the forgotten detection substrate for ligand-binding assay-based bioanalysis.

Jordan G, Stubenrauch KG, Heinrich J, Staack RF.

Bioanalysis. 2017 Feb;9(4):407-418. doi: 10.4155/bio-2016-0225. Epub 2017 Jan 20.

PMID:
28103697
4.

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.

Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G.

EMBO Mol Med. 2016 Nov 2;8(11):1265-1288. doi: 10.15252/emmm.201505889. Print 2016 Nov.

5.

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.

Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, Askoxylakis V, Taylor JW, Lu-Emerson C, Batista A, Kirkpatrick ND, Jung K, Snuderl M, Muzikansky A, Stubenrauch KG, Krieter O, Wakimoto H, Xu L, Munn LL, Duda DG, Fukumura D, Batchelor TT, Jain RK.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4476-81. doi: 10.1073/pnas.1525360113. Epub 2016 Apr 4.

6.

Proposal for a harmonized descriptive analyte nomenclature for quantitative large-molecule bioanalysis.

Heinrich J, Staack RF, Stubenrauch KG, Papadimitriou A.

Bioanalysis. 2015 Dec;7(24):3057-62. doi: 10.4155/bio.15.218. Epub 2015 Oct 27. No abstract available.

7.

Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies.

Dengl S, Hoffmann E, Grote M, Wagner C, Mundigl O, Georges G, Thorey I, Stubenrauch KG, Bujotzek A, Josel HP, Dziadek S, Benz J, Brinkmann U.

FASEB J. 2015 May;29(5):1763-79. doi: 10.1096/fj.14-263665. Epub 2015 Feb 10.

8.

Noninvasive measurement of pharmacokinetics by near-infrared fluorescence imaging in the eye of mice.

Dobosz M, Strobel S, Stubenrauch KG, Osl F, Scheuer W.

J Biomed Opt. 2014 Jan;19(1):16022. doi: 10.1117/1.JBO.19.1.016022.

PMID:
24474508
9.

Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.

Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, Herting F, Yu S, The HH, Martarello L, Gassner C, Stubenrauch KG, Munro K, Augustin HG, Thomas M.

Clin Cancer Res. 2013 Dec 15;19(24):6730-40. doi: 10.1158/1078-0432.CCR-13-0081. Epub 2013 Oct 4.

10.

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies.

Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, Schwaiger M, Stubenrauch KG, Sustmann C, Thomas M, Scheuer W, Klein C.

Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92. doi: 10.1073/pnas.1019002108. Epub 2011 Jun 20.

11.

A high-throughput test to detect C.E.R.A. doping in blood.

Lamon S, Giraud S, Egli L, Smolander J, Jarsch M, Stubenrauch KG, Hellwig A, Saugy M, Robinson N.

J Pharm Biomed Anal. 2009 Dec 5;50(5):954-8. doi: 10.1016/j.jpba.2009.06.038. Epub 2009 Jun 27.

PMID:
19625154
12.

CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability.

Ji C, Kopetzki E, Jekle A, Stubenrauch KG, Liu X, Zhang J, Rao E, Schlothauer T, Fischer S, Cammack N, Heilek G, Ries S, Sankuratri S.

J Biol Chem. 2009 Feb 20;284(8):5175-85. doi: 10.1074/jbc.M808745200. Epub 2008 Dec 19.

Supplemental Content

Loading ...
Support Center